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Objectives   Bioassays of rats exposed to acrylonitrile have consistently detected an elevated incidence of central
nervous system (CNS) cancer. In contrast, epidemiologic studies have not found a statistically stable increase in
CNS cancer mortality. The purpose of this paper is to examine whether or not CNS cancers predicted from the
most appropriate inhalation bioassay in rats are consistent with CNS cancers observed in 3 recent, large
epidemiologic studies.
Methods   A linearized multistage model was fit to dose-response data from a rat inhalation bioassay to estimate
carcinogenic potency. This potency was applied to epidemiologic studies of acrylonitrile-exposed workers. After
adjustment for less than complete lifetime follow-up in the epidemiologic studies, consistency was examined
between CNS cancers predicted by the model fit to the animal data for the exposure levels and sample sizes of the
epidemiologicy studies and the CNS cancers observed in the epidemiologic studies.
Results   The model predicted totals of 17.7, 3.6, and 7.6 CNS cancer deaths for the studies. These predictions
were not far from the observed CNS cancer deaths (12, 6, and 6) and were well within their 95% confidence
intervals of 6.9—22.3, 2.2—13.1, and 2.2—13.1, respectively.
Conclusions   The CNS cancer potency estimated from the best available inhalation bioassay was consistent
with the observed deaths in the epidemiologic studies as long as continuous lifetime exposure was chosen as the
exposure metric. The lack of observed excess in CNS cancer among the studied workers may have been due to
low exposures, insufficient follow-up times, or both.
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time, interspecies comparison.
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Acrylonitrile, a group 2B carcinogen as rated by the In-
ternational Agency for Research on Cancer (IARC) (1),
is widely used in the production of acrylic fibers, res-
ins, and nitrile elastomers and also as an intermediate
in the production of adiponitrile and acrylamide (2). In
the mid-1970s, approximately 125 000 workers in the
United States (US) were potentially exposed to acrylo-
nitrile during its production and use (3). Since then, its
worldwide consumption has increased (2). The produc-
tion of acrylonitrile and acrylic fibers has been moving
to newly industrialized nations, where the regulation and
monitoring of exposures may not be as stringent (4).
Epidemiologic studies of acrylonitrile-exposed
workers and bioassays of acrylonitrile-exposed animals
are apparently contradictory. Whether rats are exposed
to acrylonitrile by gavage, drinking water, or inhalation,
bioassays consistently show elevated incidences of
cancer in the mammary gland, Zymbal gland, and par-
ticularly the central nervous system (CNS) (5). In con-
trast, none of the epidemiologic studies, which were re-
cently reviewed by Collins & Aquavella (6), found a
large or statistically stable increase in CNS cancer inci-
dence or mortality among exposed workers. CNS can-
cer is difficult to study in human populations because it
is relatively rare. The annual mortality rate is currently
around 5 per 100 000 (7). Overall survival averages only
1—3 years (8).
In 1993, Ward & Starr (9) concluded that the occu-
pational epidemiologic studies had sufficient statistical
power to detect the CNS cancer risk predicted from bi-
oassays in which acrylonitrile was administered orally,
and their analysis was updated in 1999 by Collins &
Strother (10), who concluded likewise that the most re-
cent epidemiologic studies were not consistent with the
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risk from acrylonitrile exposure predicted from animal
data. Against this background, the American Conference
of Government Industrial Hygienists (ACGIH) recent-
ly changed their classification of acrylonitrile from an
A2 suspected human carcinogen to an A3 confirmed
animal carcinogen with unknown relevance to humans
(11)
Because the route of exposure may be a key deter-
minant of potency and because workers appear to be
predominantly exposed by inhalation (1), this paper, in
contrast to the analysis of Ward & Starr (9) or Collins
& Strother (10), compares predictions from the inhala-
tion bioassay in rats with CNS cancers observed in the
3 recent, large epidemiologic studies that included quan-
titative exposure levels for acrylonitrile-exposed work-
ers. For this purpose, we estimated the CNS cancer po-
tency of acrylonitrile in rats on the basis of an inhala-
tion bioassay (Quast J, Schuetz D, Balmer M, Gushow
T, Park C, McKenna M. A two-year toxicity and onco-
genicity study with acrylonitrile following inhalation
exposure in rats. Prepared by the Toxicology Research
Laboratory, Health and Environmental Sciences, Dow
Chemical, Midland, Michigan, United States, for the
Chemical Manufacturing Association in 1980, unpub-
lished observations) and, unlike Ward & Starr (9) or
Collins & Strother (10), applied the potency to the ac-
tual observed follow-up time in the epidemiologic stud-
ies. By calculating the number of deaths predicted for
the actual follow-up time of the workers and compar-
ing them with the observed number of deaths and their
confidence intervals, we explored the role of dose and
follow-up time in explaining the apparently contradic-
tory results for CNS cancer and exposure to acryloni-
trile. This approach has been used previously to evalu-




We focused on inhalation bioassays in animals because
workers are exposed to acrylonitrile primarily by this
route. Quast et al exposed Sprague-Dawley (Spartan
strain) rats to acrylonitrile concentrations of 20 ppm or
80 ppm, 6 hours a day, 5 days a week for 2 years, and
reported a statistically significant increased incidence
of brain or spinal cord tumors (benign and malignant)
for both the males and females. No CNS tumors were
found in the control rats, while CNS tumors were found
in 4 of 99 male rats exposed to 20 ppm and in 22 of 99
male rats exposed to 80 ppm. Of the other 2 inhalation
bioassays (15, 16), one (15) has limited value for esti-
mating cancer risk because the exposure and follow-up
were subchronic, and the other (16) began dosing the
rats while they were still in utero, an exposure scenario
unlikely among workers. We therefore selected the
Quast et al, inhalation bioassay with its standard expo-
sure scenario.
Epidemiologic studies
Collins & Strother (10) identified 11 unique follow-up
studies and 1 case-referent study that examined the as-
sociation between acrylonitrile exposure and CNS can-
cer. Using meta-analysis techniques, they calculated a
summary relative risk of 1.1 [95% confidence interval
(95% CI) 0.8—1.5]. However, only 3 epidemiologic
studies — a National Cancer Institute (NCI) multiplant
study in the United States (17), a Dutch multiplant study
(18), and a study of 2 DuPont plants in the southeastern
part of the United States (19) — relate CNS mortality
to quantitative exposure levels. The summary relative
risk for these 3 studies was 1.0 (95 CI 0.6—1.5) (6).
None of these studies demonstrated a strong statistical-
ly stable elevation in risk or a positive dose-response
relationship between cumulative exposure to acryloni-
trile and the risk of CNS cancer mortality. Neverthe-
less, these 3 cohorts were large, had an extended fol-
low-up time, and quantified exposure estimates for in-
dividual cohort members. Considered on the basis of the
framework for using epidemiologic data in risk assess-
ment developed by Hertz-Picciotto, these are all cate-
gory 2 studies (12). They therefore can be used to eval-
uate the plausibility of the quantitative risk estimated
from the animal dose-response data.
Estimating excess lifetime risk
The linearized multistage model was fit to the Quast et
al dose-response data using the software package Glo-
bal 86 (20). The model assumes a linear nonthreshold
dose-response relationship and takes the following form:
P(dHEC) = 1 – exp[–q1dHEC–q2(dHEC)2],
where P(dHEC) is the lifetime risk of cancer at dose dHEC,
dHEC is the human equivalent concentration, q1 is the es-
timated low dose potency (obtained by maximizing the
likelihood given the rat dose-response data), and q2 is
the coefficient for the quadratic dose term (which does
not materially affect the risk at low doses).
The cancer guidelines proposed by the US Environ-
mental Protection Agency (EPA) (21) advocate using a
biologically based model to translate experimental ex-
posure concentrations (dA) to dHEC; however, no such
model is available for acrylonitrile at this time. We
therefore followed the EPA default recommendation
(22, 23) summarized in the following equation:
dHEC = equivalent continuous lifetime exposure (λA/λH),
where λA/λH is the ratio of the blood-to-gas air
partition coefficient for acrylonitrile in rats to the same
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coefficient in humans. Following the example of Felter
& Dollarhide (24), we assumed λA/λH to be unity. Fi-
nally, the predicted excess lifetime risk of CNS cancer
in humans was calculated by substituting the equivalent
continuous lifetime exposure in the human epidemiolo-
gy study (dH), for dHEC in equation 1 after q1 and q2 were
estimated from the modeling of the rat data. For com-
parison, we also made calculations using (i) cumulative
exposure for the species conversion, (ii) the maximum
likelihood potency estimated by Felter & Dollarhide
(24), and (iii) the maximum likelihood potency estimat-
ed by Ward & Starr (11) from drinking water bioassays.
Predicted cancers of the central nervous system in the
human cohorts
The predicted excess lifetime risks were used to char-
acterize the risk of the 3 cohorts of acrylonitrile-exposed
workers. Because most of the workers were not followed
for their entire lifetime, we adjusted the resulting pre-
dicted CNS deaths for the actual follow-up time. These
adjusted predictions for excess mortality were added to
the expected (background) CNS cancer deaths. The pre-
dicted total was then compared with the observed CNS
cancer deaths and their confidence intervals. Similarly,
to take account of the uncertainty in the estimated po-
tency, the upper confidence limit of the total predicted
deaths was compared with the observed number of
deaths. An epidemiologic study was judged consistent,
or at least not inconsistent, with the animal bioassay if
the 95% confidence interval of the observed deaths in
the cohort surrounded the number of deaths predicted
by the extrapolation.
Proportion of lifetime risk accumulated by
epidemiologic cohorts
The proportion of lifetime risk accumulated by a cohort
was estimated as follows: (i) the expected number of
CNS cancer deaths in each cohort was divided by the
number of workers to estimate average background risk,
(ii) the average cumulative “lifetime” risk of CNS can-
cer death by 74 years of age for males in the United
States was calculated using a lifetable constructed from
US male, 1990—1994, age-specific all-cause (25) and
brain cancer death rates (26) [For the Dutch cohort,
Dutch 1990—1994 age-specific rates were used (per-
sonal communication, Jan Hoogenboezem, The Nether-
lands Central Bureau of Statistics], (iii) the ratio of step
i to step ii estimates the proportion of lifetime risk ac-
cumulated by a cohort. Finally, the predicted excess
CNS cancer deaths obtained from the animal-based po-
tency were multiplied by the estimated proportion of
lifetime risk accumulated by the cohort. This last step
accounted for the animal potency being based on a full
(rat) lifetime, while workers were observed for partial
lifetimes. The adverse consequences of failing to adjust
for different study designs and follow-up times in ani-
mal bioassays and epidemiologic studies when the re-
sults of the 2 study types are compared have been high-
lighted previously (27).
Summary of three human cohorts
We compared the total of the predicted CNS cancer
deaths from the NCI, Dutch, and DuPont cohorts to the
95% confidence interval of the observed deaths derived
from the Collins & Strother (10) summary relative risk
for the 3 studies. The summary was judged consistent,
or at least not inconsistent, with the animal bioassay if
the 95% confidence interval of the observed deaths sur-




Table 1 shows the conversion of the intermittent bio-
assay exposure rates and the intermittent exposure rates
in the epidemiologic studies to equivalent continuous
lifetime exposure rates. As is frequently the case, the
rats in the lowest dosed group in the Quast et al study
were exposed to a substantially greater equivalent con-
tinuous lifetime exposure rate than were the most high-
ly exposed workers. For example, the equivalent
Table 1. Summary of the inhalation bioassay and epidemiologic studies with quantitative exposure estimates.
Study Daily exposure Exposure time Cumulative exposure Continuous lifetime
    (ppm)    (years)     (ppm-years) exposure (ppm)
Quast et al, unpublished study 1980 (rats) 20 2   40   3.57a
80 2 160 14.37a
NCI, Blair et al 1998 (17) (humans)  .. ..     4.026b   0.0118c
Dutch, Swaen et al 1998 (18) (humans)  .. ..     7.31d   0.0214c
DuPont, Wood et al 1998 (19) (humans)  .. ..   57.67e   0.168c
a Cumulative exposure × (5/7 days exposed) × (6/24 hours exposed) / (2-year average lifetime).
b Mean (Blair, 1998 personal communication to Mark Schulz).
c Cumulative exposure × (240/365 days exposed) × (8/24 hours exposed) / (75 year average lifetime).
d Mean (Swaen, 2000 personal communication to Mark Schulz).
e Mean as reported in Wood et al (19).
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Table 2. Proportion of lifetime risk accumulated in selected epidemiologic studies. (CNS = central nervous system)
Study cohort Number in cohort Expected number of deaths Average cumulative lifetime Proportion of lifetime
from CNS cancer background risk of deaths risk accumulatedb
from CNS cancera
NCI [Blair et al (17)] 16 889 17.14 0.00101 0.27
Dutch [Swaen et al (18)] 2 842 3.45 0.00121 0.35c
DuPont [Wood et al (19)] 2 559 5.31 0.00208 0.55
a Expected number of deaths from CNS cancer / number in cohort.
b Average cumulative lifetime background risk of deaths from CNS cancer / 0.0037661, which is the average cumulative lifetime background risk for deaths
from CNS cancer by the age of 74 years among males in the United States and was calculated from a lifetable based on 1990—1994 age-specific all-cause
(25) and brain-cancer death rates (26) for males in the United States.
c Average cumulative lifetime background risk for death from CNS cancer / 0.0037661, which is the average cumulative lifetime background risk for death
from CNS cancer by the age of 74 years among Dutch males and was calculated from a lifetable based on 1990—1994 age-specific all-cause and brain-
cancer death rates for Dutch males (personal communication from The Netherlands Central Bureau of Statistics, 2000).
continuous lifetime exposure of the DuPont cohort was
0.168 ppm. In contrast, the continuous lifetime exposure
rate of the rats was 3.57 ppm.
Predicted mortality
Table 2 shows the adjustment factors for the average
portion of lifetime risk accumulated for each of the 3
occupational cohorts. These factors ranged from 0.27 to
0.55. The estimated acrylonitrile potency for CNS can-
cer based on the Quast et al rat data was 0.00954 per
ppm. The 95% upper confidence limit of the potency
was 0.0213 per ppm. When the estimated potency was
applied to the epidemiologic studies, the lifetime pre-
dicted excess CNS deaths were 1.90 in the NCI cohort,
0.58 in the Dutch cohort, 4.11 in the DuPont cohort, and
6.59 in the combined cohort (table 3). These values rep-
resent the excess CNS cancer deaths predicted to occur
if all workers were followed to death or “complete” life-
time. However, when adjusted for the proportion of life-
time risk accumulated in the corresponding epidemio-
logic studies (table 2), the predicted excess was reduced
to 0.51 for the NCI cohort, 0.20 for the Dutch cohort,
Table 3. Comparison of observed CNS cancer deaths with deaths predicted from animal dose-response data. (CNS = central nervous
system, 95% CI = 95% confidence interval, MLE = maximum likelihood estimate)
Study cohort Potencya Excess lifetime Excess Adjusted excess Predicted
riskb deathsc deathsd deathse
NCI [Blair et al (17)] 12 6.9—22.3 0.00954 0.000112 1.90 0.51 17.65
(0.0213) (0.000251) (4.23) (1.14) (18.28)
0.180f 0.002117 35.75 9.65 26.79
0.0178g 0.000209 3.54 0.95 18.09
0.00085h 0.00342i 57.70 15.58 32.72
Dutch [Swaen et al (18)] 6 2.2—13.1 0.00954 0.0002 0.58 0.20 3.65
(0.0213) (0.00045) (1.29) (0.45) (3.90)
0.180f 0.00384 10.91 3.79 7.24
0.0178g 0.00038 1.08 0.37 3.82
0.00085h 0.00619 17.60 6.11 9.56
DuPont [Wood et al (19)] 6 2.2—13.1 0.00954 0.001605 4.11 2.26 7.57
(0.0213) (0.003579) (9.16) (5.04) (10.35)
0.180f 0.029865 76.42 42.03 47.34
0.0178g 0.002991 7.65 4.21 9.52
0.00085h 0.04778i 122.27 67.25 72.56
All 3 studies combined 24 15.5—38.9 0.00954 .. 6.59 2.97 28.87
(0.0213) .. (14.68) (6.63) (32.53)
0.180f .. 123.08 55.47 81.37
0.0178g .. 12.27 5.53 31.43
0.00085h .. 197.57 88.94 114.84
a MLE of the potency, in deaths/ppm, based on fitting the multistage model to the data of Quast et al using continuous lifetime exposure as the exposure
metric, the 95% upper confidence limit being given below in parentheses.
b 1 – exp(–qd), where q is the potency and d is the continuous lifetime exposure from table 1, the 95% upper confidence limit being given below in
parentheses.
c Excess lifetime risk × number in cohort, from table 2, the 95% upper confidence limit being given below in parentheses.
d Excess deaths × proportion of lifetime risk accumulated, from table 2, the 95% upper confidence limit being given below in parentheses.
e Expected deaths from table 2 + adjusted excess deaths, the 95% upper confidence limit being given below in parentheses.
f MLE potency (deaths/ppm) estimated from drinking water bioassays by Ward & Starr (11).
g MLE potency (deaths/ppm) estimated from Quast et al data by Felter & Dollarhide (24).
h MLE potency (deaths/ppm-years) based on fitting multistage model to the data of Quast et al using cumulative exposure as the exposure metric.
i d is the cumulative exposure from table 1 rather than the continuous lifetime exposure.
j Sum of the expected deaths from table 2 + adjusted excess deaths.
Observed deaths
N            95% CI
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2.26 for the DuPont cohort, and 2.97 for the combined
cohort (table 3).
Table 3 also shows the total CNS deaths predicted
on the basis of summing the expected (background)
CNS deaths and the adjusted excess predicted from acry-
lonitrile exposure. For each cohort and for the cohorts
combined, the 95% confidence interval of the observed
CNS cancer deaths easily included the total predicted
deaths. When the 95% upper confidence limit of the po-
tency was applied to the epidemiologic studies, the pre-
dicted deaths were slightly greater but still within the
95% confidence interval of the observed deaths (table
3).
In table 3, we have also shown that the total predict-
ed deaths fell outside the 95% confidence interval of the
observed deaths for the NCI cohort, the DuPont cohort,
and the combined cohort when the potency based on the
drinking-water studies was applied [as was done by
Ward & Starr (9) and Collins & Strother (10)] or when
the exposure metric was cumulative exposure rather than
continuous lifetime exposure rate and thus did not ac-
count for differences in the average lifetime of rats and
humans.
Discussion
Extrapolation, using the multistage model, from the in-
halation bioassay dose-response data to the epidemio-
logic data resulted in a prediction of CNS cancer death
totals that was similar to the number of observed CNS
deaths. In addition, these predictions lay within each re-
spective 95% confidence interval for the 3 epidemio-
logic cohorts studied (table 3). An important element of
our analysis was the adjustment of the animal-based risk
estimate for the proportion of lifetime risk accumulated
in each epidemiologic cohort. This adjustment substan-
tially reduces the predicted excess of CNS cancers due
to acrylonitrile exposure, by 73% for the NCI cohort,
by 65% for the Dutch cohort, and by 45% for the Du-
Pont cohort (table 2). The reductions are large because
the cumulative probability of CNS cancer death increas-
es at a greater than linear rate with age (26). This ad-
justment is particularly large for the NCI and Dutch co-
horts because both cohorts were apparently young at the
time they were studied.
Thus we found that neither the Dutch study nor the
NCI study was inconsistent with our animal-based risk
estimate (table 3). Even the results of the DuPont study
with its older cohort and the 3-study summary (10) were
not inconsistent with the animal-based risk estimate de-
rived from the inhalation bioassay. In contrast, Collins
& Strother (10) concluded that their summary of the
NCI, Dutch, and DuPont studies was inconsistent with
their animal-based risk estimate, and, earlier, Ward &
Starr (9) concluded that a subset of the NCI study (28)
was inconsistent with their animal-based risk estimate.
Three factors contributed to the higher risks predicted
by Collins & Strother (10) and Ward & Starr (9). First,
their adjustment for less-than-lifetime follow-up as-
sumed a constant CNS cancer rate across all ages from
the start of exposure. Since CNS cancer rates increase
at older ages (26), we achieved a more realistic adjust-
ment using the proportion of lifetime risk accumulated.
Second, they imputed a higher estimate of average cu-
mulative exposure based on estimates of average daily
exposure offered by Santodonato (29) for highly ex-
posed acrylonitrile workers during the historical time
period of interest. We based our lower mean cumula-
tive exposure estimates for each cohort on the exposure
assessments developed specifically for each cohort.
Third, they applied a CNS cancer potency (1.8 × 10–1
per ppm) derived from ingestion bioassays; this poten-
cy is 18 times larger than that based on the inhalation
bioassay. We relied on the Quast et al rat bioassay that
used the same route as that through which workers are
exposed to acrylonitrile.
We found that the CNS potency estimated by Ward
& Starr (9) and used by Collins & Strother (10) was in-
consistent with the results of all but the Dutch cohort
(table 3) even when we applied an appropriate partial
lifetime risk adjustment and the cohort-specific expo-
sure assessments used throughout our analyses. Recent-
ly, Felter & Dollarhide (24) estimated a CNS cancer
potency for acrylonitrile. They used the risk assessment
guidelines proposed by the EPA in 1996 (21) and esti-
mated a CNS cancer potency (1.78 × 10-2 per ppm) for
acrylonitrile that is only slightly higher than ours. As
we did, these authors selected the Quast et al inhalation
bioassay dose-response data as the basis of their poten-
cy, but they excluded rats that died before the 1st rele-
vant tumor was observed. We found that the Felter &
Dollarhide CNS cancer potency was not inconsistent
with the results of the epidemiologic studies.
Using the 95% upper confidence limit of the poten-
cy, we estimated the extra risk from exposure to acry-
lonitrile for a lifetime of work (8 hours/day, 240 days/
year, and 45 years/70 years) at the threshold limit value
of 2 ppm (11) of the ACGIH as 6 in 1000. This level is
somewhat greater than the 1 in 1000 lifetime risk level
that the Occupational Safety and Health Administration
hopes to achieve with its permissible exposure levels
(30).
As in all risk assessments, we made several assump-
tions in our analysis. The linear nonthreshold dose-re-
sponse relationship assumed by our multistage model is
a major source of uncertainty in this analysis. The multi-
stage model is biologically plausible and usually pro-
vides the most health protective extrapolation to low
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doses. As such, it has long been the default choice of
the US EPA (5).
Current evidence suggests that acrylonitrile is not di-
rectly genotoxic. No DNA adducts of acrylonitrile or its
metabolites have been identified in rat brain (31). How-
ever, recently, increased levels of 8-oxodeoxyguanos-
ine have been found in rats at doses of acrylonitrile sim-
ilar to those that produced increases in brain tumors (32),
and increased levels of 8-hydroxy-2’deoxyguanosine
have been found in acrylonitrile-treated Syrian hamster
embryo cells in parallel with a dose-dependent increase
in morphologically transformed Syrian hamster embryo
cell colonies (33). Both Whysner et al (32) and Zhang
et al (33) have suggested a possible role for oxidative
DNA damage in this carcinogenic process. Nevertheless,
the effects of acrylonitrile that produce 8-oxodeoxygua-
nosine are not yet understood; the dosimetry evidence
is not conclusive either for or against our assumption of
low-dose linearity for the carcinogenicity of acryloni-
trile.
To extrapolate data on rats to humans, we assumed
the ppm concentration of acrylonitrile in rats to be
equivalent to the same ppm concentration in humans.
This approach is advocated by the US EPA (22) for in-
halation bioassays in which the toxic agent is partially
soluble in water. The US EPA notes that this assump-
tion is based on limited knowledge (22). However, phys-
iologically based pharmacokinetic models for acryloni-
trile which could accurately estimate the effective dose
to the tissue of interest are not yet available for humans.
We converted the exposure rates of the rats to hu-
man equivalent concentrations according to the method
of the US EPA (23). This conversion accounts for the
different average life spans of rats (2 years) and humans
(70 years) in the industrialized world. The resulting con-
tinuous lifetime exposure rates in the Quast et al inha-
lation study were 30 to 1000 times higher than the cor-
responding average continuous lifetime exposure rates
of the acrylonitrile-exposed cohorts (table 1). General-
ly, bioassays must use much larger exposure rates than
those that occur among human populations in order to
achieve sensitivity to detect effects with a modest
number of animals (34).
Our estimate of human acrylonitrile potency is sen-
sitive to the exposure metric chosen for the animal to
human conversion. The lifetime cumulative exposures
in the bioassay and in the epidemiologic studies are
more similar in magnitude than the continuous lifetime
exposure rates are (table 1). When we replicated our
analyses using equivalence by lifetime cumulative ex-
posure rather than by average continuous lifetime ex-
posure rate, we found that the results for the NCI co-
hort, the DuPont cohort, and the summary of the 3 co-
horts were no longer consistent with those of the Quast
et al inhalation bioassay (table 3). Use of lifetime
cumulative exposure equivalence, as opposed to dose
rate equivalence, is known to yield much higher esti-
mates of human risk, as it did in this study (35, 36).
Finally, with regard to policy, our results suggest that
the ACGIH should reconsider its recent change in the
classification of acrylonitrile from an A2 suspected hu-
man carcinogen to an A3 confirmed animal carcinogen
with unknown relevance to humans. This study demon-
strates that the CNS cancer potency estimated from the
best available inhalation bioassay is not inconsistent
with the observed mortality in 3 recent large epidemio-
logic studies of workers exposed to acrylonitrile when
continuous lifetime exposure is selected as the exposure
metric. The data suggest that a risk of 6/1000 at the cur-
rent threshold limit value of 2 ppm of the ACGIH is not
contradicted by any human study. An A3 classification
by the ACGIH would appear to imply some discordance
between animal and human data (11), while our results
suggest that such a judgment is, at the minimum, pre-
mature.
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